- Development and clinical evaluation of a monkeypox antigen-detecting rapid
- 2 diagnostic test

8

- 3 Nobuyuki Kurosawa<sup>1,2</sup>, Tatsuhiko Ozawa<sup>1,2</sup>, Kousei Ozawa<sup>3</sup>, Masayuki Shimojima<sup>4</sup>,
- 4 Madoka Kawahara<sup>4</sup>, Fumi Kasuya<sup>5</sup>, Wakaba Okada<sup>5</sup>, Mami Nagashima<sup>5</sup>, Kenji
- 5 Sadamasu<sup>5</sup>, Masae Itamochi<sup>6</sup>, Hideki Tani<sup>6</sup>, Yoshitomo Morinaga<sup>2, 7</sup>, Kosuke Yuhara<sup>8</sup>,
- 6 Jun Okamoto<sup>8</sup>, Haruna Ichikawa<sup>8</sup>, Takashi Kawahata<sup>8</sup>, Tomomi Yamazaki<sup>8</sup>, Masaharu
- 7 Isobe<sup>1,2</sup>
- 9 Department of Life Sciences and Bioengineering, Laboratory of Molecular and
- 10 Cellular Biology, Faculty of Engineering, Academic Assembly, University of Toyama,
- 11 3190 Gofuku, Toyama-shi, Toyama, 930-8555, Japan
- 12 <sup>2</sup> Center for Advanced Antibody Drug Development, University of Toyama, 3190
- 13 Gofuku, Toyama-shi, Toyama, 930-8555, Japan
- 14 <sup>3</sup> Department of Life Sciences and Bioengineering, Laboratory of Molecular and
- 15 Cellular Biology, Graduate School of Pharma-Medical Sciences, University of Toyama,
- 16 3190 Gofuku, Toyama-shi, Toyama, 930-8555, Japan
- <sup>4</sup> Department of Virology I, National Institute of Infectious Diseases, Toyama 1-23-1,
- 18 Shinjuku-ku, Tokyo 162-8640, Japan
- <sup>5</sup> Department of Microbiology, Tokyo Metropolitan Institute of Public Health, 3-24-1
- 20 Hyakunincho, Shinjuku-ku, Tokyo, Japan
- 21 <sup>6</sup> Department of Virology, Toyama Institute of Health, 7-1 Nakataikoyama, Imizu-shi,
- 22 Toyama 939-0363, Japan
- <sup>7</sup> Department of Microbiology, Toyama University Graduate School of Medicine and
- 24 Pharmaceutical Sciences, 2630 Sugitani, Toyama, 930-0194, Japan
- 25 <sup>8</sup> Biotechnology Research Laboratory, TOYOBO Co., Ltd., 10-24, Toyo-Cho,
- 26 Tsuruga-Shi, Fukui, 914-8550, Japan
- 28 Corresponding author

29 Nobuyuki Kurosawa 30 kurosawa@eng.u-toyama.ac.jp 31 Department of Life Sciences and Bioengineering, Laboratory of Molecular and Cellular 32 Biology, Faculty of Engineering, Academic Assembly, University of Toyama, Toyama, 33 Japan 34 35 Abstract 36 To address the global emergence of monkeypox after the 2022 epidemic, a rapid and 37 accurate diagnostic tool is needed at the point of care to identify individuals infected with 38 monkeypox virus (MPXV) to prevent and control the spread of the virus. We designed an 39 antigen-detecting rapid diagnostic test that exclusively detects MPXV without 40 cross-reacting with the vaccinia virus by developing monoclonal antibodies against the 41 MPXV nuclear capsid protein A5L (MPXV-A5L). The test established a limit of 42 detection sensitivity of 0.5 ng/mL of MPXV-A5L, with high sensitivity (87%) for 43 clinical specimens collected from MPXV patients, a qPCR cycle threshold value ≤ 25 44 and 100% specificity for qPCR-negative samples. The test is an ideal rapid diagnostic 45 tool for supporting clinical decision-making for people suspected of having MPXV 46 infection in resource-poor settings. 47 **Abbreviations** 48 antigen-detecting rapid diagnostic test, Ag-RDT; monkeypox virus, MPXV; orthopoxvirus, 49 OPXV; quantitative polymerase chain reaction, qPCR; lateral flow 50 immunochromatography assay, LFIA; vaccinia viruses, VACV; cycle threshold, Ct. 51 **Keywords** 52 Monkeypox; Antigen-detecting rapid diagnostic test; Monoclonal antibody; Lateral 53 flow immunochromatography assay; qPCR; clinical evaluation 54 1. Introduction 55 Monkeypox is a zoonotic disease caused by the monkeypox virus (MPXV), a highly 56 pathogenic double-stranded DNA virus classified in the genus orthopoxvirus (OPXV)

57 of the family *Poxviridae* (Karagoz et al., 2023; Mitja et al., 2023; Yu, Shi, and Cheng, 58 2023). There are two genotypes of MPXV: Congo Basin strains (clade I) and West 59 African strains (clades IIa and IIb). Although monkeypox was confirmed mainly in 60 African countries, an epidemic of clade IIb MPXV was ongoing globally in early 2022, 61 and 88,288 infected people and approximately 150 deaths were reported from 112 62 countries on July 10, 2023 (Malik et al., 2023). Infection occurs through close contact 63 with respiratory droplets, body fluids, skin lesions, or the blood of infected people or 64 animals. After an incubation period ranging from 7 to 16 days, the affected individuals 65 experience prodromal symptoms such as fever and general malaise, followed by the 66 appearance of a skin rash that can be mistaken for those seen in chickenpox, measles, 67 syphilis, and hand-foot-and-mouth disease (Zahmatyar et al., 2023) (Khattak et al., 68 2022) (Silva et al., 2023). Most healthy individuals experience mild disease progression, 69 but immunocompromised patients, children, and pregnant women can experience severe 70 symptoms (Schwartz et al., 2023; Silva et al., 2023). Older adults who have received 71 smallpox vaccination acquired cross-protective immunity against MPXV. However, 72 younger generations, who had not been vaccinated against smallpox, have no immunity 73 to MPXV (Reynolds and Damon, 2012). Although the WHO declared the end of the 74 monkeypox emergency, it called for sustained efforts for the long-term management of 75 this virus (Bunge et al., 2022). 76 The detection of viral genes via polymerase chain reaction (PCR) is the gold standard 77 method for MPXV diagnosis (Huang et al., 2023). However, these methods are 78 designed for use in centralized laboratory settings. An antigen-detecting rapid 79 diagnostic test (Ag-RDT) based on a lateral flow immunochromatography assay (LFIA) 80 is an effective method for diagnosing MPXV through point-of-care testing in patients 81 with monkeypox symptoms (Bunge et al., 2022). Several commercial and in-house 82 Ag-RDTs have been developed for the diagnosis of MPXV by using antibodies against 83 vaccinia virus (VACV) A27 or MPXV A29, an ortholog of VACV A29 (Mitja et al., 84 2023) (Huang et al., 2023; Hughes et al., 2014; Roumillat, Patton, and Davis, 1984). 85 However, it is difficult to diagnose MPXV accurately, as most tests are not specific and 86 may cross-react with VACV, which circulates in wild and domestic animals with 87 occasional transmission to humans in close contact with these animals. Thus, an 88 accurate MPXV Ag-RDT is vital for the effective treatment and control of MPXV 89 infection, especially in areas where VACV is endemic (Miranda et al., 2017).

MPXV A5L, an ortholog of VACV A4L, is a highly conserved 39-kDa

91 immunodominant nucleocapsid protein that plays a role in the assembly and 92 disassembly of the virion (Risco et al., 1999). The abundance and low mutation rate of 93 MPXV A5L make it an ideal antigen for detecting MPXV via LFIA. In this work, we 94 designed an MPXV Ag-RDT by developing a set of monoclonal antibodies that target 95 MPXV A5L while not cross-reacting with VACV. We confirmed assay specificity via a 96 panel of viral and bacterial pathogens. The MPXV Ag-RDT showed high sensitivity 97 (87%) for clinical specimens collected from MPXV patients, with a qPCR cycle 98 threshold (Ct) value  $\leq 25$  and a specificity of 100% for qPCR-negative samples. The 99 MPXV Ag-RDT is suitable for point-of-care use in low-resource settings and can 100 support the implementation of isolation measures to reduce the risk of transmission. 101 2. Materials and methods 102 2.1 Ethics approval 103 All animal and biosafety experiments were carried out at the University of Toyama and 104 Toyama Institute of Health after approval from the Committee for Laboratory Animal 105 Care and Use (A2022ENG-1 and G2022eng-1). Experiments with live VACV and 106 MPXV were performed under biosafety levels 2 and 3, respectively, at the National 107 Institute of Infectious Diseases. The clinical study was approved by the Ethical Review 108 Board of the Tokyo Metropolitan Institute of Public Health (5 KenKenKen 3712). 109 2.2 Antigen preparation 110 Chemically synthesized MPXV A5L and VACA A4L cDNA were inserted into the 111 pCold ProS2 vector (Takara Bio, Japan) and transformed into E. coli Tuner (DE3) 112 pLacI (Novagen). Recombinant proteins were purified from the soluble fraction of the E. 113 coli lysate via Ni-chelate affinity chromatography (Capturem His-tagged Purification 114 Miniprep Kit, Takara Bio, Japan) followed by dialysis with PBS. The purified proteins 115 were then concentrated using Amicon® Ultra-15 centrifugal filter units (EMD 116 Millipore) and used as antigens. The MPXV peptide (LKDLMSSVEKDMRQLQAET) 117 was conjugated to keyhole limpet hemocyanin (KLH) via the C-terminal cysteine 118 residue.

#### 2.3 Immunization

120 Anesthetized rats or rabbits were immunized three times intramuscularly at the tail base 121 with 50 µg of A5L protein. Iliac lymph nodes were surgically removed from the 122 euthanized animals. Anesthetized New Zealand White rabbits were immunized three 123 times subcutaneously with 500 µg of KLH conjugates of MPXV A5L peptide, and 124 peripheral blood lymphocytes were surgically corrected from the euthanized animals. 125 2.4 Development of monoclonal antibodies 126 The isolation of rat antigen-specific plasma cells was performed as previously described 127 (Kurosawa et al., 2012). Briefly, rat lymph node cells fixed with ice-cold 128 phosphate-buffered saline (PBS) containing 2% paraformaldehyde were stained with 129 DyLight 488-labeled ProS-MPXV-A5L, DyLight 550-labeled ProS-Vaccinia-A4L, 130 DyLight 650-labeled anti-rat IgG and DAPI in PBS containing 0.1% Triton X-100 (PBST). MPXV A5L-specific plasma cells, defined as ProS-MPXV-A5L High and 131 IgG<sup>High</sup>, were single-sorted via a JSAN Cell Sorter (Bay Bioscience). The isolation of 132 133 rabbit antigen-specific plasma cells was performed as previously described (Ozawa et 134 al., 2012). Briefly, IgG<sup>+</sup> cells isolated from A5L-immunized rabbits were cultured on a 135 chip coated with 10 μg/mL rabbit IgG antibody at 37 °C for 3 hours. The chip was 136 incubated with biotinylated MPXV A5L peptide (10 µg/mL) for 30 min and stained 137 with Cy3-labeled streptavidin to detect antigen-specific plasma cells. Molecular cloning 138 of immunoglobulin heavy and light chain genes from single-isolated plasma cells, followed by the expression of recombinant antibodies, was performed as previously 139 140 described (Kurosawa et al., 2012; Ozawa et al., 2012). Antibodies were expressed via 141 the Expi293 Expression System (Thermo Fisher Scientific) and purified using protein A 142 affinity chromatography followed by size-exclusion chromatography (Cytiva). 143 2.5 Immunofluorescence analysis 144 A plasmid encoding Vaccinia A4L and a series of MPXV A5L mutants were 145 constructed via PCR and inserted into the pCDNA3.1 or pEFMycHis plasmid. Each 146 plasmid was transfected into HEK293 cells using the FuGENE 6 Transfection Reagent 147 (Promega), and the cells were cultured for two days. After fixation with PBS containing 148 4% paraformaldehyde, the cells were permeabilized with PBST and stained with the 149 indicated antibodies. Images were captured with an Operetta High Content Imaging 150 System (PerkinElmer) or a BZ-X700 all-in-one fluorescence microscope (Keyence).

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

2.6 Preparation of a lateral flow immunochromatographic assay The #230-9 antibody (0.1 mg) and 100 µL of NanoAct cellulose particles A (BL2: Dark Navy, Asahi Kasei Corporation) were mixed in 900 μL of 10 mM Tris-HCl buffer (pH 8.0) and allowed to stand at 37 °C for 120 minutes. The reaction was stopped by the addition of 12 mL of 100 mM boric acid buffer (pH 8.0) containing 1% casein. The antibody-cellulose particles suspended with 8 mL of 62 mM boric acid buffer (pH 9.2) containing 15% sucrose were uniformly applied to the entire surface of a glass fiber diagnostic pad (GFDX001050, Millipore) at an application rate of 60 µL/cm, followed by drying at 45 °C for 30 minutes to prepare the conjugation pad. #2S-36 and goat-derived anti-rabbit IgG polyclonal antibodies were applied to Hi-Flow Plus 120 Membrane Cards (HF120, Millipore) at predetermined locations in a volume of 1.0 μL/cm with a line width of approximately 1 mm. The membrane was dried for 30 min at 40 °C. The conjugate pad was overlaid onto the nitrocellulose membrane with a 3 mm overlap. The sample pad and the absorbent pad were placed on either end of the nitrocellulose membrane with 3 mm and 5 mm of overlap, respectively. The immunochromatographic specimens were cut into strips 4 mm wide and 60 mm long and placed in a plastic cassette (K007, Shengfeng Plastic). 2.7 Immunochromatographic device sensitivity evaluation Recombinant MPXV A5L was used as a quality control throughout the test manufacturing process. Recombinant MPXV A5L and virus-infected cell lysate were diluted with sample diluent solution (100 mM Tris buffer, pH 8.5, 0.877% sodium chloride, 0.2% Tween 20 and 0.9% Triton X), and an aliquot of 110 uL was dispensed via pipette into the sample well of the cassette. After 15 minutes, the presence of lines was visually checked. Immediately after visual inspection, images were captured, and the signal intensity at both the test and control line locations was quantified using ImageJ (NIH). 2.8 Viruses VACV and MPXV were propagated and titrated as described previously with a modification in that RK13 cells were used instead of Vero cells (Saijo et al., 2006). The SPL-2A7 strain (clade IIb) of MPXV was isolated using RK13 cells from specimens

181 derived from patients with suspected monkeypox and brought to the National Institute 182 of Infectious Diseases for an administrative inspection of monkeypox. 183 **2.9 ELISA** 184 RK13 cells infected with VACV or MPXV were washed with PBS and treated with 1% 185 NP40-containing PBS for cell lysis. Uninfected cells were also prepared and treated in 186 parallel. The supernatants of the cell lysates were used as antigens for ELISA. ELISA 187 plates (Nunc Maxisorp) were coated with cell lysates at a 1:1,000 dilution overnight, 188 and blocking was performed with 5% skim milk. The plates were incubated with 189 primary antibodies at the indicated concentrations, followed by further incubation with 190 secondary antibodies labeled with horseradish peroxidase. Colorization was performed 191 by the addition of ABTS (Roche), and the absorbance was measured at 405 nm with a 192 microplate reader (Bio-Rad iMark). 193 2.10 Clinical sample collection and real-time qPCR assay 194 The samples sent to the Tokyo Metropolitan Institute of Public Health (TMIPH) as a 195 part of the active epidemiological surveillance of suspected cases of monkeypox were 196 used for this study. Viral DNA was extracted from the samples (skin lesions; crusts and 197 blister swabs) via a QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). Real-time 198 qPCR to detect MPXV (targeting the F3L region) was performed using a QuantStudio 199 12K Flex (Thermo Fisher Scientific, Waltham, MA, USA) and a QuantiTect Probe PCR 200 Kit (Qiagen) according to the pathogen detection manual of the National Institute of 201 Infectious Diseases, Japan 202 (https://www.niid.go.jp/niid/images/lab-manual/mpox20230531.pdf). The viral load of 203 the MPXV was expressed as the Ct value detected by real-time PCR as previously 204 described (Kasuya et al., 2023). 205 2.11 Statistical analysis 206 The sensitivity, specificity, positive predictive value, and negative predictive value were 207 estimated via the Clopper Pearson exact method, along with corresponding 95% 208 confidence intervals.

# **3. Results**

## 3.1 Development and screening of mAbs against A5L

To develop anti-MPXV A5L antibodies, we immunized rats with recombinant MPXV A5L and rabbits with the KLH-conjugated MPXV A5L peptide. Immunoglobulin heavy and light chain gene cloning from antigen-specific single plasma cells resulted in the production of 128 rat and three rabbit mAbs. The activity of these mAbs was examined via immunofluorescence staining of HEK293 cells expressing MPXV A5L. Among the 61 MPXV A5L-positive mAbs tested, five rat mAb clones and one rabbit mAb clone were selected on the basis of their unique complementarity-determining region 3 sequences. Epitope mapping of these mAbs by using HEK293 cells expressing a series of N-terminal deletion mutants of MPXV A5L revealed that the epitope for #2-22 was located on amino acids 1-100, #2S-36 on amino acids 100-180, #1-28 on amino acids 180-225 and #1-35, #3-7, and #230-9 on amino acids 225-281 (Fig. 1). For further characterization of these mAbs, an ELISA screen was performed using MPXV- or VACV-infected Vero cell lysates as antigens (Fig. 1B). #1-28, #1-35, #2-22, #3-7, and #230-9 reacted with the MPXV- and VACV-infected cell lysates. #2S-36 reacted with only the MPXV-infected cell lysate.




Fig. 1. Antibody development for MPXV detection.

230 (A) Immunofluorescence images of HEK293 cells expressing a series of C-terminal 231 deletion mutants of MPXV A5L stained with the indicated mAbs. A schematic diagram 232 of the deletion mutants of MPXV A5L; the locations of the epitopes for each mAb are 233 shown. 234 (B) ELISA screening of mAbs using MPXV (SPL-2A7, a clade IIb strain isolated in 235 2022 in Japan), VACV (strain LC16m8), or mock-infected RK13 cell lysates as the 236 antigen. The cells were lysed in 1% NP40/PBS, and the supernatants, which were 237 diluted 1000-fold in PBS, were added to each well of a 96-well plate. Serially diluted 238 mAbs were added to the plates. The figure reports the values from a single experiment. 239 These results indicate that #2S-36 is a suitable antibody that can differentiate MPXV 240 from VACV. An ELISA was performed to select clones to be paired with #2S-36. The 241 results revealed that #1-28, #3-7, #1-35, and #230-9 had nearly identical sensitivities for 242 MPXV A5L, whereas 2-22 did not (Supplemental Fig. 1A). Among these clones, 243 #230-9, which recognizes the C-terminus of MPXV A5L and partially cross-reacted 244 with VACV, was selected. 245 3.2 Development of a rapid antigen test for the detection of MPXV 246 The #2S-36/#230-9 set was tested in immunochromatography pairs, with one antibody 247 conjugated to cellulose nanoparticles and one antibody absorbed into a nitrocellulose 248 membrane. The test strips prepared by colloidal cellulose labeling with #230-9 and 249 T□lines with #2S-36 presented greater detection sensitivity than the reverse 250 combination did (Supplemental Fig. 1B). The kinetic analyses by surface plasmon 251 resonance highlighted the fast association (kon) and slow dissociation (koff) rates for 252 the interaction with MPXV A5L, resulting in equilibrium dissociation constants (K<sub>D</sub> values) of  $0.82 \times 10^{-9}$  M for #230-9 and  $1.5 \times 10^{-9}$  M for #2S-36, respectively 253 254 (Supplemental Fig. 2). Based on the test strips assay, an Ag-RDT was established with 255 #2S-36 used as a capture Ab in the test (T) line and colloidal cellulose labeled #230-9 as 256 a detection Ab absorbed on a pad. The control (C) line was incubated with a goat 257 anti-rabbit IgG antibody. The analytical performance of the Ag-RDT was evaluated by 258 testing the recombinant MPXV A5L as a standard sample in the concentration range of 259 0 to -1000 ng/mL. Naked-eye observation revealed that the A5L concentration of 0.5 260 ng/mL caused a slight but distinguishable difference in the test line intensity compared 261 with that of the negative control (Fig. 2).




Fig. 2 Limit of detection of the MPXV Ag-RDT using recombinant MPXV A5L as the antigen.

(A) Photographs representing the LFIA strips and test zones. Recombinant MPXV A5L diluted with sample diluent solution and an aliquot of  $110~\mu L$  was dropped into the immunochromatographic device. After 15 minutes, the presence of lines was visually checked. Immediately after visual inspection, images were captured, and the signal intensity at both the test and control line locations was quantified via ImageJ. The results of two experimental replicates are shown. The visual limit of detection was set by two independent observers at the lowest A5L concentration at which the T line disappeared in the two strips. Naked-eye judgment: positive (+) or negative (-). C, control. T, test.

(B) Standard curve plot of the T/C value (%) on the Y-axis and the logarithm of MPXV A5L on the X-axis.

A standard curve was generated by plotting the relative band intensity ratio (T/C) against the MPXV A5L concentration, which increased with increasing protein concentration. It was quantitative in the range of 0 to 25.0 ng/mL, with a correlation coefficient of 0.9994. Increasing the antigen concentration above 1000 ng/mL led to a decrease in the intensity of the C line, whereas the intensity of the T line continued to increase, affecting the T/C ratio. This is likely due to fewer free-capture antibodies binding to the C line, as more antibodies are used to form immune complexes. The limit of detection (LOD) of the Ag-RDT was 440 plaque-forming units (PFU)/test for clade IIb SPL-2A7 and 2112 PFU/test for clade I Congo8 virus. Cross-reactivity with VACV was not detected at concentrations under 1.76×10<sup>4</sup> PFU/test (Fig. 3). The Ag-RDT did not cross-react with viruses causing diseases with symptoms similar to those of MPXV, such as the measles virus, Coxsackie virus type A6, A16, and enterovirus A71 (Supplemental Fig. 3). The Ag-RDT was negative for all 20 bacterial lysates present in the airway and oral cavity (Supplemental Fig. 4).




Fig. 3 Analytical sensitivity and specificity of the MPXV Ag-RDT using serially diluted stocks of isolates of MPXV or VACV. An aliquot of 75  $\mu$ l of the viral mixture was diluted with 75  $\mu$ l of sample dilution buffer, and 110  $\mu$ l was subsequently added to the cassette. Visual judgment was independently determined by two people.

When concentrations of human or bovine serum, ranging from 0.2% to 8%, were spiked with MPXV (11,000 PFU) and then applied to the Ag-RDT, no significant inhibition of the test line intensity was observed, indicating that the serum did not significantly affect the performance of the assay (Supplemental Fig. 5).

# 3.3 Point-of-care clinical evaluation studies

We next conducted a study to compare the sensitivity of the Ag-RDT with that of qPCR for MPXV clinical specimens collected as dry swabs (Kasuya et al., 2023). The qPCR-positive samples were divided into high (Ct value of  $\leq \Box 25$ ) and low (Ct value of 26~40) groups. As shown in Fig. 4 and Table 1, The Ag-RDT detected 87% (20 out of 23 swabs; 95% CI, 66%-97%) of the samples in the high group but failed to detect samples in the low group (0 out of 27 swabs; 95% CI, 0%-13%). The Ag-RDT results were consistent with those of the qPCR-negative samples, with a specificity of 100% (0 out of 10 swabs; 95% CI, 0%-31%).




Fig. 4. The MPXV Ag-RDT-positive and antigen-negative samples were compared via a box plot of the qPCR Ct values. Each symbol represents one sample. The center lines show the medians. The box limits are quartiles 1 and 3, and the whiskers represent the maximum and minimum values.

### 4. Discussion

In this study, we designed an MPXV Ag-RDT by developing an antibody set that can differentiate MPXV from VACV. The Ag-RDT provided accurate results in less than 15

316 minutes and exhibited high selectivity and analytical sensitivity for MPXV. A 317 concordance study of clinical specimens collected as dry swabs revealed that the 318 Ag-RDT showed 87% sensitivity in samples with Ct values of  $\leq \square$  25 and a specificity of 319 100% with qPCR-negative samples. 320 Since the global outbreak of monkeypox in 2022, combined with the increasing danger 321 of other zoonotic orthopoxvirus infections, there has been a need to develop a 322 MPXV-specific diagnostic tests. Among the MPXV proteins, the virus envelope protein 323 A29, which plays an important role in virus host cell interactions, is one of the most 324 extensively studied targets (Ahsendorf et al., 2019; Bengali, Satheshkumar, and Moss, 325 2012; Howard, Senkevich, and Moss, 2008). Several in-house and commercial 326 Ag-RDTs have been developed by using antibodies specific to A29. However, most of 327 these are cross-reactive with VACV (de Lima et al., 2023; Dubois, Hammarlund, and 328 Slifka, 2012). Owing to the increasing incidence of occasional outbreaks of VACV in 329 South America, the use of such tests can result in misdiagnosis as MPXV (Miranda et 330 al., 2017). Recently, mAbs that can distinguish MPXV from VACV have been 331 developed and applied to Ag-RDTs (Davis et al., 2023; Hughes et al., 2014; Ye et al., 332 2023). Although MPVX typically displays a low number of mutations, such as those 333 associated with DNA viruses, the mutation ratio of MPVX isolated after the 2022 334 outbreak surpassed the standard mutation rate of the virus (Yashavarddhan et al., 2023). 335 Consequently, antibodies that recognize the A29 epitope may not work as effectively in 336 the future because of viral mutations, which could cause decreased sensitivity and 337 inaccurate results. To prepare for unexpected mutant strains of MPXV that may evade 338 current tests, it is crucial to develop an additional set of antibodies targeting a different 339 protein of MPXV. 340 Among orthopoxviruses, MPXV A5L is one of the major core immunogenic and 341 conserved proteins (Risco et al., 1999). The two antibodies targeting MPXV A5L are 342 suitable for use in rapid diagnostic tests because they can bind to a distant epitope with 343 a high association rate constant (kon) and a low dissociation rate constant (koff). These 344 characteristics enable the antibodies to quickly bind to the antigen and maintain strong 345 binding. This makes them ideal for designing species-specific serological assays 346 targeting MPXV A5L. No cross-reactivity was observed for viruses causing diseases 347 with symptoms similar to those of monkeypox, bacteria present in the airway and oral 348 cavity and interfering substances in the serum. No loss of sensitivity was observed in

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

this test when the samples were stored at room temperature for one year after manufacturing. The viral load has been found to be the most important factor for determining antigen test sensitivity (Lim et al., 2023). Our data showed that the Ag-RDT has enough sensitivity to identify contagious patients with  $Ct \le 25$ . Therefore, this test could guide initial decisions regarding isolation and management and reduce the need for a qPCR test in the case of positive results. It is important to note that the sensitivity of the test decreased when the qPCR Ct value was greater than 25. As a result, this test may not be appropriate for detecting the virus in the prodromal stage, as the viral load may be too low to be detected by the Ag-RDT. Prior to clinical implementation, this device requires several improvements to enhance its sensitivity and performance. Conclusion The MPXV Ag-RDT is capable of sensitive and specific detection of MPXV in virus-infected clinical specimens, distinguishing it from other skin infections. The MPXV Ag-RDT has potential for use in point-of-care settings. **Transparency declaration** All the authors have nothing to disclose. **Funding** This research was supported by grants from the Japan Agency for Medical Research and Development (AMED) to Masaharu Isobe (19187977, 20333128 and 22723616) and Tatsuhiko Ozawa (JP24ama121010), as well as from The Toyama Pharmaceutical Valley Development Consortium (no grant number assigned) to Masaharu Isobe and Japan Society for the Promotion of Science, Japan (Grant in Aid for Scientific Research B) (22H02875) to Nobuyuki Kurosawa. The funders had no role in the study design, data collection and analysis, publishing decisions, or the preparation of the manuscript. **CRediT** authorship contribution statement Nobuyuki Kurosawa: Writing – original draft, Methodology, Investigation, Formal analysis, Data curation. Tatsuhiko Ozawa: Methodology, Investigation, Formal analysis.

377 Madoka Kawahara: Methodology, Investigation, Formal analysis. Masayuki 378 Shimojima: Methodology, Investigation, Formal analysis. Madoka Kawahara: 379 Methodology, Investigation, Formal analysis. Fumi Kasuya: Methodology, 380 Investigation, Formal analysis. Wakaba Okada: Methodology, Investigation, Formal 381 analysis. Mami Nagashima: Methodology, Investigation, Formal analysis. Kenji 382 Sadamasu: Methodology, Investigation, Formal analysis. Masae Itamochi: Methodology, 383 Investigation, Formal analysis. Hideki Tani: Methodology, Investigation, Formal 384 analysis. Yoshitomo Morinaga: Methodology, Investigation, Formal analysis. Masaharu 385 Isobe: Funding acquisition, Supervision. 386 **Declaration of competing interest** 387 The authors declare that they have no known competing financial interests or personal 388 relationships that could have appeared to influence the work reported in this paper. 389 Data availability 390 The data will be made available upon request. 391 Acknowledgments 392 We thank past and current members of our laboratory for fruitful discussions. We also 393 thank Y. Nohara and K Takai for their technical support. 394 References 395 Ahsendorf, H.P., Gan, L.L., Eltom, K.H., Abd El Wahed, A., Hotop, S.K., Roper, R.L., 396 Beutling, U., Broenstrup, M., Stahl-Hennig, C., Hoelzle, L.E. and Czerny, C.P., 397 2019. Species-Specific Conservation of Linear Antigenic Sites on Vaccinia 398 Virus A27 Protein Homologs of Orthopoxviruses. Viruses 11. 399 Bengali, Z., Satheshkumar, P.S. and Moss, B., 2012. Orthopoxvirus species and strain 400 differences in cell entry. Virology 433, 506-12. 401 Bunge, E.M., Hoet, B., Chen, L., Lienert, F., Weidenthaler, H., Baer, L.R. and Steffen, 402 R., 2022. The changing epidemiology of human monkeypox-A potential threat? 403 A systematic review. PLoS Negl Trop Dis 16, e0010141. 404 Davis, I., Payne, J.M., Olguin, V.L., Sanders, M.P., Clements, T., Stefan, C.P., 405 Williams, J.A., Hooper, J.W., Huggins, J.W., Mucker, E.M. and Ricks, K.M.,

406 2023. Development of a specific MPXV antigen detection immunodiagnostic 407 assay. Front Microbiol 14, 1243523. 408 de Lima, L.F., Barbosa, P.P., Simeoni, C.L., de Paula, R.F.O., Proenca-Modena, J.L. 409 and de Araujo, W.R., 2023. Electrochemical Paper-Based Nanobiosensor for 410 Rapid and Sensitive Detection of Monkeypox Virus. ACS Appl Mater Interfaces 411 15, 58079-58091. 412 Dubois, M.E., Hammarlund, E. and Slifka, M.K., 2012. Optimization of peptide-based 413 ELISA for serological diagnostics: a retrospective study of human monkeypox 414 infection. Vector Borne Zoonotic Dis 12, 400-9. 415 Howard, A.R., Senkevich, T.G. and Moss, B., 2008. Vaccinia virus A26 and A27 416 proteins form a stable complex tethered to mature virions by association with the 417 A17 transmembrane protein. J Virol 82, 12384-91. 418 Huang, X., Xiao, F., Jia, N., Sun, C., Fu, J., Xu, Z., Cui, X., Huang, H., Qu, D., Zhou, J. 419 and Wang, Y., 2023. Loop-mediated isothermal amplification combined with 420 lateral flow biosensor for rapid and sensitive detection of monkeypox virus. 421 Front Public Health 11, 1132896. 422 Hughes, L.J., Goldstein, J., Pohl, J., Hooper, J.W., Lee Pitts, R., Townsend, M.B., 423 Bagarozzi, D., Damon, I.K. and Karem, K.L., 2014. A highly specific 424 monoclonal antibody against monkeypox virus detects the heparin binding 425 domain of A27. Virology 464-465, 264-273. 426 Karagoz, A., Tombuloglu, H., Alsaeed, M., Tombuloglu, G., AlRubaish, A.A., 427 Mahmoud, A., Smajlovic, S., Cordic, S., Rabaan, A.A. and Alsuhaimi, E., 2023. 428 Monkeypox (mpox) virus: Classification, origin, transmission, genome 429 organization, antiviral drugs, and molecular diagnosis. J Infect Public Health 16, 430 531-541. 431 Kasuya, F., Negishi, A., Kumagai, R., Yoshida, I., Murakami, K., Fujiwara, T., 432 Hasegawa, M., Harada, S., Amano, A., Inada, M., Saito, S., Morioka, S., 433 Ohmagari, N., Sugishita, Y., Miyake, H., Nagashima, M., Sadamasu, K. and 434 Yoshimura, K., 2023. Genetic Characteristics of the Virus Detected in the First 435 Mpox Imported Case in Tokyo, Japan. Jpn J Infect Dis 76, 259-262. 436 Khattak, S., Rauf, M.A., Ali, Y., Yousaf, M.T., Liu, Z., Wu, D.D. and Ji, X.Y., 2022. 437 The monkeypox diagnosis, treatments and prevention: A review. Front Cell 438 Infect Microbiol 12, 1088471. 439 Kurosawa, N., Yoshioka, M., Fujimoto, R., Yamagishi, F. and Isobe, M., 2012. Rapid 440 production of antigen-specific monoclonal antibodies from a variety of animals. 441 BMC Biol 10, 80.

- 442 Lim, C.K., McKenzie, C., Deerain, J., Chow, E.P.F., Towns, J., Chen, M.Y., Fairley,
- 443 C.K., Tran, T. and Williamson, D.A., 2023. Correlation between monkeypox
- viral load and infectious virus in clinical specimens. J Clin Virol 161, 105421.
- 445 Malik, S., Ahmed, A., Ahsan, O., Muhammad, K. and Waheed, Y., 2023. Monkeypox
- Virus: A Comprehensive Overview of Viral Pathology, Immune Response, and
- 447 Antiviral Strategies. Vaccines (Basel) 11.
- 448 Miranda, J.B., Borges, I.A., Campos, S.P.S., Vieira, F.N., de Azara, T.M.F., Marques,
- 449 F.A., Costa, G.B., Luis, A., de Oliveira, J.S., Ferreira, P.C.P., Bonjardim, C.A.,
- da Silva, S.L.M., Eiras, A.E., Abrahao, J.S., Kroon, E.G., Drumond, B.P., Paglia,
- 451 A.P. and Trindade, G.S., 2017. Serologic and Molecular Evidence of Vaccinia
- Virus Circulation among Small Mammals from Different Biomes, Brazil. Emerg
- 453 Infect Dis 23, 931-938.
- 454 Mitja, O., Ogoina, D., Titanji, B.K., Galvan, C., Muyembe, J.J., Marks, M. and Orkin,
- 455 C.M., 2023. Monkeypox. Lancet 401, 60-74.
- 456 Ozawa, T., Piao, X., Kobayashi, E., Zhou, Y., Sakurai, H., Andoh, T., Jin, A., Kishi, H.
- and Muraguchi, A., 2012. A novel rabbit immunospot array assay on a chip
- allows for the rapid generation of rabbit monoclonal antibodies with high
- 459 affinity. PLoS One 7, e52383.
- 460 Reynolds, M.G. and Damon, I.K., 2012. Outbreaks of human monkeypox after
- delta cessation of smallpox vaccination. Trends Microbiol 20, 80-7.
- 462 Risco, C., Rodriguez, J.R., Demkowicz, W., Heljasvaara, R., Carrascosa, J.L., Esteban,
- 463 M. and Rodriguez, D., 1999. The vaccinia virus 39-kDa protein forms a stable
- complex with the p4a/4a major core protein early in morphogenesis. Virology
- 465 265, 375-86.
- Roumillat, L.F., Patton, J.L. and Davis, M.L., 1984. Monoclonal antibodies to a
- 467 monkeypox virus polypeptide determinant. J Virol 52, 290-2.
- 468 Saijo, M., Ami, Y., Suzaki, Y., Nagata, N., Iwata, N., Hasegawa, H., Ogata, M.,
- Fukushi, S., Mizutani, T., Sata, T., Kurata, T., Kurane, I. and Morikawa, S.,
- 470 2006. LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of
- 471 the membrane protein B5R, protects monkeys from monkeypox. J Virol 80,
- **472** 5179-88.
- 473 Schwartz, D.A., Ha, S., Dashraath, P., Baud, D., Pittman, P.R. and Waldorf, K.A., 2023.
- Mpox Virus in Pregnancy, the Placenta, and Newborn. Arch Pathol Lab Med
- **475** 147, 746-757.
- 476 Silva, M.S., Coutinho, C., Torres, T.S., Peixoto, E.M., Bastos, M.O., Mesquita, M.B.,
- Tavares, I.C., Andrade, H.B., Reges, P.P., Martins, P.S., Echeverria-Guevara, A.,

478 Moreira, R.I., Lessa, F.C.S., Hoagland, B., Nunes, E.P., Cardoso, S.W., Veloso, 479 V.G., Grinsztejn, B. and Group, I.N.-F.M.S., 2023. Mpox severity and 480 associated hospitalizations among people living with HIV and related 481 immunosuppression in Brazil. AIDS. 482 Yashavarddhan, M.H., Bohra, D., Rana, R., Tuli, H.S., Ranjan, V., Rana, D.S. and 483 Ganguly, N.K., 2023. Comprehensive overview of 2022 human monkeypox 484 outbreak and its pathology, prevention, and treatment: A strategy for disease 485 control. Microbiol Res 277, 127504. 486 Ye, L., Lei, X., Xu, X., Xu, L., Kuang, H. and Xu, C., 2023. Gold-based paper for antigen detection of monkeypox virus. Analyst 148, 985-994. 487 488 Yu, X., Shi, H. and Cheng, G., 2023. Mpox Virus: Its Molecular Evolution and 489 Potential Impact on Viral Epidemiology. Viruses 15. 490 Zahmatyar, M., Fazlollahi, A., Motamedi, A., Zolfi, M., Seyedi, F., Nejadghaderi, S.A., 491 Sullman, M.J.M., Mohammadinasab, R., Kolahi, A.A., Arshi, S. and Safiri, S., 492 2023. Human monkeypox: history, presentations, transmission, epidemiology, 493 diagnosis, treatment, and prevention. Front Med (Lausanne) 10, 1157670. 494